Status asthmaticus medical therapy

Status Asthmaticus Microchapters
Home
Patient Information
Overview
Pathophysiology
Causes
Differentiating Status Asthmaticus from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Status asthmaticus medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Status asthmaticus medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Status asthmaticus medical therapy
CDC on Status asthmaticus medical therapy
Status asthmaticus medical therapy in the news
Blogs on Status asthmaticus medical therapy
Directions to Hospitals Treating Status asthmaticus
Risk calculators and risk factors for Status asthmaticus medical therapy

For patient information click here Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Initial severity assessment is evaluated using arterial blood gas and pulmonary function test and aggressive therapy is initiated to prevent progression to respiratory failure

Medical Therapy

• Non-invasive ventilation using C-PAP or tight-fitting face mask may be used to reduce the work of breathing without intubation.

• Endotracheal intubation and mechanical ventilation should be used with caution in asthmatics who are non-responsive to medical therapy or non-invasive methods of ventilation, due to the substantial risk of barotrauma. Common indications include impending respiratory arrest, severe hypoxia non-responsive to supplemental oxygen, CO2 retention with PaCO₂ greater than 50 mmHg, acidosis and/or altered mental status.

• Supplemental oxygen via nasal canula or face mask is recommended to alleviate severe hypoxia. Oxygen saturation is maintained above 92% and is monitored using pulse Oximetry

• Helium with oxygen mixture has shown to reduce airway resistance and thereby reduce the work of breathing and also improve bronchodilator efficacy.

• Use of magnesium sulphate administered either IV or nebulized in addition to β2-agonists remains controversial.

• Mainstay drugs for the management include nebulized β2-agonists such as albuterol, salbutamol or terbutaline, parenteral steroids such as hydrocortisone or prednisolone and theophylline

• Anti-cholinergics such as ipratropium bromide may be indicated in patients who are unable to tolerate inhaled β2-agonists.

• In patients non-responsive to nebulized bronchodilator, IV-aminophylline or oral-leukotriene inhibitor may be used.

Therapy based on the severity of the disease assessed by Arterial Blood Gas Analysis

Stage 1

• Hyperventilation with normal PO₂
• No hypoxemia
• Patients may benefit from nebulized ipratropium used adjunctive to β2-agonist therapy

Stage 2

• Hyperventilation with hypoxemia (low PO₂ and PCO₂)
• Patients may require corticosteroids in addition to bronchodilator therapy

Stage 3

• CO2 retention due to respiratory muscle fatigue
• Markedly elevated PCO2 levels are an indicator for mechanical ventilation
• Aggressive β2-agonist therapy along with parenteral steroids and/or theophylline is indicated

Stage 4

• Severe hypoxia with markedly elevated PCO₂
• FEV1 lower than 20% predicted is suggestive of an impending respiratory arrest that may require intubation and mechanical ventilation
• Metered-dose inhalation of β2-agonist and anticholinergics are recommended. Administration of parenteral steroids and/or theophylline has also shown to be beneficial.